Antibody

10개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved10 programs
AntibodyCurated CoreFDAJohnson & JohnsonApproved

nipocalimab (Imaavy, M281, nipocalimab-aahu)

Generalized myasthenia gravis (AChR or MuSK antibody-positive, age ≥12); warm autoimmune hemolytic anemia · FcRn

#FcRn#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 27Status Approved
AntibodyLimited DatastaleSanofiPhase 3

Isatuximab SAR650984 (Isatuximab SAR650984)

Immune System Disorder · Plasma Cell Myeloma

#PlasmaCellMyeloma#Antibody#Phase3#monoclonal-antibody#ImmuneSystemDisorder+2
Trials 39Status Active
AntibodyLimited DatastaleWeill Medical College of Cornel…Phase 3

Higher Dose of Rituximab (Higher Dose of Rituximab)

Immune Thrombocytopenic Purpura · Immune Thrombocytopenic Purpura

#ImmuneThrombocytopenicPurpura#Antibody#Phase3#monoclonal-antibody#Weill
Trials 1Status Active
AntibodyLimited DatastaleImmuneering CorporationPhase 2

Treatment Group E (IMM-1-104 + pembrolizumab, IMM-1-104 + pembrolizumab (Treatment Group E))

Advanced Solid Tumor; Pancreatic Adenocarcinoma · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#monoclonal-antibody#PancreaticAdenocarcinoma+1
Trials 1Status Recruiting
AntibodyLimited DatastaleMerckPreclinical

pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab (Immune Checkpoint Inhibitors, Immune Checkpoint Inhibitors ( pembrolizumab, tislelizumab, sintilimab, camrelizumab, and toripalimab))

Esophageal Squamous Cell Carcinoma (ESCC) · Esophageal Squamous Cell Carcinoma (ESCC

#EsophagealSquamousCellCarcinomaE#Antibody#Preclinical#monoclonal-antibody#Merck
Trials 1Status Recruiting
AntibodyLimited DatastaleMedImmune LLCPhase 2

durvalumab (Imfinzi, MEDI6469 Plus Durvalumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 Plus Tremelimumab (MEDI6469 Plus Tremelimumab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleMedImmune LLCPhase 2

MEDI6469 plus Rituximab (MEDI6469 plus Rituximab)

Advanced Solid Tumors; Aggressive B-cell Lymphomas · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase2#monoclonal-antibody#AggressiveB-cellLymphomas+1
Trials 1Status Discontinued
AntibodyLimited DatastaleNewcastle UniversityApproved

Solu-medrone, Mabthera (Solu-medrone, Mabthera)

Autoimmune Adrenocortical Failure · Autoimmune Adrenocortical Failure

#AutoimmuneAdrenocorticalFailure#Antibody#Approved#monoclonal-antibody#Newcastle
Trials 1Status Active
AntibodyLimited DatastaleRocheApproved

eltrombopag combining rituximab (eltrombopag combining rituximab)

Primary Immune Thrombocytopenia (ITP) · Primary Immune Thrombocytopenia (ITP)

#PrimaryImmuneThrombocytopeniaITP#Antibody#Approved#monoclonal-antibody#Roche
Trials 1Status Recruiting